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ABSTRACT 
 
Development and Analytical Validation of an Enzyme-Linked Immunosorbent Assay 
(ELISA) for the Measurement of Feline Alpha1-Proteinase Inhibitor (fα1-PI) in Serum 
and Feces and the Evaluation of Fecal fα1-PI Concentrations in Cats with Idiopathic 
Inflammatory Bowel Disease or Gastrointestinal Neoplasia. (August 2012) 
Kathrin Fetz Burke, med. vet., Dr. med. vet.; University of Veterinary Medicine, 
Hannover, Germany 
Chair of Advisory Committee: Dr. Jörg M. Steiner 
 
Alpha1-proteinase inhibitor (α1-PI) has been shown to be a useful marker of 
gastrointestinal protein loss in some species. The objectives of this study were, first, to 
develop and analytically validate an ELISA for the measurement of α1-PI in feces and 
serum from cats, and, second, to evaluate fecal α1-PI concentrations in healthy cats and 
cats with chronic gastrointestinal disease.  
The lower detection limits of the ELISA were 0.02 g/L for serum and 0.04 µg/g 
for feces. The observed-to-expected (O/E) ratios for serial dilutions of serum and fecal 
samples ranged from 100.0 to 129.7% (mean ±SD: 112.2 ±9.9%) and 103.5 to 141.6% 
(115.6 ±12.8%), respectively. The O/E ratios for samples spiked with seven known 
concentrations of α1-PI ranged from 82.3 to 107.8% (94.7 ±7.6%) for serum and 78.5 to 
148.7% (96.8 ±18.2%) for feces. The coefficients of variation for intra-assay and inter-
assay variability were <7.9% and <12.1% for serum, and 5.3%, 11.8%, and 14.2% and 
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7.7%, 10.2%, and 20.4% for feces, respectively. Reference intervals were 0.6 to 1.4 g/L 
for serum and up to 1.6 µg/g for feces. We conclude that this ELISA is sufficiently 
linear, accurate, precise, and reproducible.  
For the clinical evaluation, twenty cats with clinical signs of chronic 
gastrointestinal disease and 20 healthy control cats were enrolled. The diseased cats were 
grouped into two groups: mild to moderate idiopathic inflammatory bowel disease (IBD) 
(Group A; n=8) and severe IBD or neoplastic disease (Group B; n=12), based on 
histopathology results of endoscopic biopsies. Fecal α1-PI concentrations and serum 
concentrations of total protein, albumin, globulin, cobalamin, folate, pancreatic lipase 
immunoreactivity, and trypsin-like immunoreactivity were determined. Nineteen of the 
20 diseased cats had increased fecal α1-PI concentrations, ranging from 1.9 to 233.6 µg/g 
(normal range: ≤1.6 µg/g). Fecal α1-PI concentrations were statistically significantly 
different between healthy cats and cats of Group A (median: 3.9 µg/g, range: 1.3 to 9.2 
µg/g, P<0.001) or cats of Group B (median: 20.6 µg/g, 4.3 to 233.6 µg/g; P<0.001), and 
also between cats of Groups A and B (P<0.01). Hypoalbuminemia, hypoproteinemia, 
and hypocobalaminemia were detected in 88%, 83%, and 56% of the diseased cats, 
respectively. Our study suggests that increased fecal α1-PI concentrations in association 
with hypoalbuminemia may be a common finding in cats with IBD or GI neoplasia. 
Furthermore, α1-PI concentrations appear to be higher in cats with severe IBD or 
confirmed GI neoplasia when compared to cats with mild to moderate IBD. 
v 
 
DEDICATION 
 
To Adam and our family  
vi 
 
ACKNOWLEDGEMENTS 
 
I would especially like to thank my committee chair Dr. Jörg Steiner and my 
committee member Dr. Jan Suchodolski for their guidance, patience, support, and most 
of all for their exceptional friendship throughout my time at the Gastrointestinal 
Laboratory.  I would also like to thank Dr. Craig Ruaux, Dr. David Williams, and Dr. 
John Broussard for their help with this project.  Further, I would like to thank my 
committee member Dr. John August for his support with this thesis.  Many thanks also 
to the entire GI lab team for all their help and friendship over the past years.  Finally, I 
would like to thank my husband Adam for his love, support, and encouragement. 
vii 
 
 TABLE OF CONTENTS 
 
              Page 
ABSTRACT ..............................................................................................................  iii 
DEDICATION ..........................................................................................................  v 
ACKNOWLEDGEMENTS ......................................................................................  vi 
TABLE OF CONTENTS ..........................................................................................  vii 
LIST OF FIGURES ...................................................................................................  ix 
LIST OF TABLES ....................................................................................................  x 
CHAPTER 
 I INTRODUCTION ................................................................................  1 
  Alpha1-Proteinase Inhibitor ............................................................  1 
Fecal α1-PI as a marker of gastrointestinal protein loss .................  3 
Gastroenteropathies with transmucosal protein loss  .....................  5 
Hypothesis and specific objectives.................................................  6 
 
 II DEVELOPMENT AND ANALYTICAL VALIDATION OF AN    
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR  
  THE MEASUREMENT OF ALPHA1-PROTEINASE INHIBITOR  
  IN SERUM AND FECES FROM CATS .............................................  7 
   Overview ........................................................................................  7 
   Introduction ....................................................................................  8 
   Materials and Methods ...................................................................  10 
   Results ............................................................................................  15 
   Discussion ......................................................................................  26 
III EVALUATION OF FECAL ALPHA1-PROTEINASE INHIBITOR 
CONCENTRATIONS IN CATS WITH IDIOPATHIC  
 INFLAMMATORY BOWEL DISEASE AND CATS WITH 
GASTROINTESTINAL NEOPLASIA ...............................................       31 
 
       Overview ........................................................................................       31 
viii 
 
CHAPTER                Page 
   Introduction ....................................................................................       32 
   Materials and Methods ...................................................................       34 
   Results ............................................................................................       38 
   Discussion ......................................................................................       47 
 IV       DISCUSSION .......................................................................................       54 
 
         V        CONCLUSIONS ...................................................................................       58        
 
REFERENCES ..........................................................................................................       59 
VITA .........................................................................................................................       68 
 
 
  
ix 
 
LIST OF FIGURES 
                                                                                                                                      Page 
 
Figure 1 Representative standard curve for the feline α1-PI ELISA .......................  23 
 
Figure 2  Variation of fecal α1-PI concentrations in three fecal samples of 20  
  healthy cats ................................................................................................  24 
 
Figure 3 Mean fecal α1-PI concentrations in healthy cats .......................................  25 
 
Figure 4  Fecal α1-PI concentrations in 20 apparently healthy cats and 20 cats 
  with chronic GI disease .............................................................................  46 
 
 
  
x 
 
LIST OF TABLES 
 
                                                                                                                                  Page 
Table 1 Results of dilutional parallelism of serum samples for the  
  feline α1-PI ELISA ....................................................................................       17 
 
Table 2 Results for dilutional parallelism of fecal extracts for the
  feline α1-PI ELISA ....................................................................................       18 
 
Table 3 Results for spiking recovery of serum samples for the 
  feline α1-PI ELISA ....................................................................................       19 
 
Table 4 Results for spiking recovery of fecal extracts of the  
  feline α1-PI ELISA ....................................................................................       20 
 
Table 5 Precision and reproducibility of serum samples for the
  feline α1-PI ELISA ....................................................................................       21 
 
Table 6 Precision and reproducibility of fecal extracts for the
  feline α1-PI ELISA ....................................................................................       22 
 
Table 7 Signalment, clinical signs, and serum concentrations of albumin,  
  globulin, total protein, and fecal α1-PI concentrations of the cats  
  with chronic GI disease ............................................................................        43 
    
Table 8 Histopathological grading, lesion localization, and histopathological  
  diagnoses of the cats with chronic GI disease. ..........................................       44 
 
Table 9 Serum concentrations of cobalamin, folate, trypsin-like immunoreactivity 
(TLI), and pancreatic lipase immunoreactivity (PLI) for the cats  
  with chronic GI disease .............................................................................       45 
1 
 
   
 
CHAPTER I 
INTRODUCTION 
 
 
ALPHA1-PROTEINASE INHIBITOR 
Alpha1-proteinase inhibitor (α1-PI) is a primarily hepatocellularly-produced 
glycoprotein that is present in various biological fluids, tissues, and cells, which is 
especially abundant in plasma. Alpha1- PI is recognized as the prototype of the family of 
serine proteinase inhibitors (serpins), which represents the third largest group of plasma 
proteins after albumin and immunoglobulins (Hibbetts et al., 1999; Travis and Salvesen, 
1983).  
The main function of α1-PI within the body consists of the regulation of various 
serine proteinases, in order to prevent excessive proteolysis in vivo.  Alpha1-PI was first 
identified in human sera by Schultze et al. (1955) and was named α1-3.5-glycoprotein, 
owing to its migration within the α1-globulin region during alkaline electrophoresis. In 
the same year, Jacobsson (1955) discovered that this protein appears to mainly inhibit 
trypsin, a serine proteinase. Therefore, the protein was renamed α1-antitrypsin a few 
years later (Schultze et al., 1962).   
 
 
____________ 
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However, other studies found that this protein shows the strongest inhibitory 
activity towards neutrophil elastase, but that it also regulates many other serine 
proteinases, including chymotrypsin, trypsin, and thrombin (Pannell et al., 1974). In 
order to reflect this broader spectrum of inhibitory activity terminologically, α1-
antitrypsin was re-named α1-PI in the veterinary literature (Pannell et al., 1974). 
However, the name α1-antitrypsin continues to be used more commonly in the human 
literature.   
The terms “protease” and “proteinase” are often used interchangeably in the 
literature, which is however incorrect. Protease is a term that encompasses 
endopeptidases or exopeptidases, while proteinases only encompass endopeptidases. 
Endopeptidases break peptide bonds of nonterminal amino acids, in contrast to 
exopeptidases, which break peptide bonds of terminal amino acids. Serine proteinases, 
such as neutrophil elastase or trypsin, are all endopeptidases, and inhibitors of these 
proteinases, such as α1-PI, are therefore correctly termed serine proteinase inhibitors 
(McDonald, 1985). 
Alpha1-PI has been identified and purified in many different species, including 
humans (Laurell et al., 1975), rhesus monkeys (Berninger and Mathis, 1976), horses 
(Patterson et al., 1991), and dogs (Melgarejo et al., 1996). In a previous study, we have 
purified and partially characterized α1-PI in cats (Fetz et al., 2004). 
In humans, α1-PI has been shown to mainly inhibit the serine proteinase 
neutrophil elastase. The importance of this function became particularly evident when 
Laurell and Eriksson (1963) first described a state of α1-PI deficiency in humans (this 
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disorder is still known as α1-antitrypsin deficiency). Patients with this condition develop 
progressive lung emphysema due to insufficient inhibition of neutrophil elastase, which 
subsequently degrades elastin in the alveoli. Alpha1-antitrypsin deficiency is now known 
to be one of the most frequent congenital disorders in humans (Graziadei et al., 1998). 
Alpha1-antitrypsin deficiency has also been associated with chronic liver disease in 
humans, which is caused by accumulation of abnormal α1-PI within hepatocytes 
(Nemeth, 1994).  Further, α1-PI has been shown to be an acute phase protein in humans 
as well as some other species, such as rabbits and rats, the plasma concentration of 
which may increase three- to four-fold during acute inflammation in humans (Alper et 
al., 1980; Koj and Regoeczi, 1978; Koj et al., 1978). 
 
FECAL α1-PI AS A MARKER OF GASTROINTESTINAL PROTEIN LOSS 
In humans and dogs, various chronic gastroenteropathies that produce 
inflammation, vascular congestion, lymphatic occlusion, or bleeding have shown to be 
associated with transmucosal loss of plasma proteins, in particular albumin. 
Traditionally, gastrointestinal protein loss has been diagnosed by the measurement of 
radioactive chromium (51Cr) in feces (Waldmann, 1961). For this method, 51Cr is 
injected intravenously, which then binds to endogenous albumin. In case of transmucosal 
protein loss, the 51Cr-labeled albumin is lost into the intestinal lumen. While albumin is 
degraded by proteolytic enzymes, the radioactivity of 51Cr can still be detected in the 
fecal matter.  This test is highly sensitive, but has important disadvantages.  Most 
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importantly this test exposes both patients and personnel to radioactivity. Also, fecal 
matter has to be collected over a period of five days.  
Because of its unique properties as a proteinase inhibitor, the measurement of α1-
proteinase inhibitor in feces was found to be a useful alternative method for the detection 
of gastrointestinal protein loss in humans and dogs (Melgarejo, 1999; Karbach, 1982). 
As α1-PI has a similar molecular mass and charge to serum albumin, plasma α1-PI tends 
to be lost into the gastrointestinal lumen whenever albumin leaks into the lumen as a 
result of gastrointestinal disease.  But unlike albumin, α1-PI is a proteinase inhibitor and 
is thus able to withstand degradation by digestive and bacterial proteases in the 
gastrointestinal lumen.  Alpha1-PI remains essentially intact in the gastrointestinal lumen 
and can therefore be quantified in feces by use of immunoassays. 
An immunoassay, more specifically an ELISA, for the measurement of α1-PI 
concentrations in fecal matter has been developed and analytically validated for use in 
dogs (Melgarejo et al., 1998), and has been shown to be clinically useful for the 
detection of protein loss in dogs with chronic GI disease (Murphy et al., 2003).  Fecal 
α1-PI concentration also may be useful in the detection of gastrointestinal protein loss in 
cats. However, immunoassays for α1-PI are highly species-specific. In a previous study, 
we have purified α1-PI from serum of cats and developed a species-specific 
radioimmunoassay for the detection of α1-PI in serum of cats (Fetz et al., 2004); 
however, further studies showed this assay not to be useful for accurate quantification of 
α1-PI in fecal matter of cats (unpublished data).  Therefore, a need to develop and 
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analytically validate an immunoassay that allows for the measurement of α1-PI in fecal 
samples from cats remained.  
 
GASTROENTEROPATHIES WITH TRANSMUCOSAL PROTEIN LOSS 
Abnormal loss of plasma proteins through the GI mucosa is also referred to as 
protein-losing enteropathy (PLE). Clinically, PLE is often identified in patients with 
hypoalbuminemia when transmucosal loss exceeds hepatic synthesis of albumin.  
The exact mechanisms leading to transmucosal protein loss during GI disease are 
not clear. In human medicine, PLE can be classified according to the main pathologic 
changes leading to protein loss through the GI mucosa as erosive GI disorders, non-
erosive GI disorders, and disorders involving increased central venous pressure or 
mesenteric lymphatic obstruction (Umar and DiBaise, 2010). In healthy individuals only 
small amounts of proteins are lost through the gut mucosa. According to a study by 
Schmidt et al. (1995), daily plasma protein loss into the GI lumen accounts for only 1 to 
2% of the total plasma protein pool. In contrast, transmucosal protein loss in patients 
with PLE may reach up to 60% of the total albumin pool (Umar and DiBaise, 2010). 
PLE can be associated with a wide spectrum of disease conditions in humans, including 
Crohn’s disease, gastric and intestinal neoplasia, systemic lupus erythematosus, or 
cardiac disease. In dogs, PLE has been mostly associated with idiopathic inflammatory 
bowel disease (IBD), intestinal lymphoma, and intestinal lymphangiectasia. In cats, there 
has been little mention of gastroenteropathies associated with protein loss. A few studies 
have reported hypoalbuminemia in cats with IBD (Baez et al., 1999; Bailey et al., 2010; 
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Jergens et al., 1992). Other authors have stated that PLE occurs less frequently in cats 
than in dogs (Peterson and Willard, 2003). However, supportive data for this hypothesis 
are lacking. 
For the diagnosis of PLE, other disorders that have the potential to cause 
hypoalbuminemia, such as protein-losing nephropathy, liver insufficiency, or cutaneous 
losses have to be excluded first. The next step will involve the confirmation of protein 
loss through the GI tract. As mentioned above, the measurement of α1-PI in feces has 
been shown to be suitable marker for GI protein loss in dogs, while studies in cats are 
not available to date.   
 
HYPOTHESIS AND SPECIFIC OBJECTIVES 
The hypotheses of this study are 1) that an enzyme-linked immunoassay can be 
used to measure α1-PI inhibitor in serum and feces of cats and 2) that fecal α1-PI 
concentrations are higher in cats with chronic GI disease compared to healthy cats.  
The objectives of this study are 1) to develop and analytically validate an 
enzyme-linked immunoassay for the measurement of α1-PI in serum and feces of cats 
and 2) to evaluate fecal α1-PI concentrations in healthy cats and cats with idiopathic 
inflammatory bowel disease or gastrointestinal neoplasia.  
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CHAPTER II 
 
DEVELOPMENT AND ANALYTICAL VALIDATION OF AN ENZYME-
LINKED IMMUNOSORBENT ASSAY (ELISA) FOR THE MEASUREMENT OF 
ALPHA1-PROTEINASE INHIBITOR IN SERUM AND FECES FROM CATS* 
 
OVERVIEW 
The objective of this study was to develop and analytically validate an ELISA for 
the measurement of alpha1-proteinase inhibitor (α1-PI) in feces and serum from cats. 
Lower detection limit, linearity, accuracy, precision, reproducibility, and reference 
intervals were determined. The lower detection limits were 0.02 g/L for serum and 0.04 
µg/g for feces. The observed-to-expected (O/E) ratios for serial dilutions of serum and 
fecal samples ranged from 100.0 to 129.7% (mean ±SD: 112.2 ±9.9%) and 103.5 to 
141.6% (115.6 ±12.8%), respectively. The O/E ratios for samples spiked with seven 
known concentrations of α1-PI ranged from 82.3 to 107.8% (94.7 ±7.6%) for serum, and 
78.5 to 148.7% (96.8 ±18.2%) for feces. The coefficients of variation for intra-assay and 
inter-assay variability were <7.9% and <12.1% for serum, and 5.3%, 11.8%, 14.2%, and 
7.7%, 10.2%, 20.4% for feces, respectively. Reference intervals were 0.6 to 1.4 g/L for 
serum and up to 1.6 µg/g for feces. We conclude that this ELISA is sufficiently linear, 
accurate, precise, and reproducible for clinical evaluation.   
____________ 
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INTRODUCTION 
Alpha1-Proteinase inhibitor (α1-PI) is a predominantly liver-produced 
glycoprotein, which protects tissues against excessive proteolysis by serine proteinases 
(Graziadei et al., 1998).  Originally α1-PI was thought to predominantly inhibit trypsin, 
and was therefore named α1-antitrypsin (Schultze et al., 1962).  Later it was found that 
many other serine proteinases are also regulated by this proteinase inhibitor, including 
neutrophil elastase, chymotrypsin, trypsin, and thrombin (Pannell et al., 1974).  In order 
to reflect this broader spectrum of inhibitory activity terminologically, α1-antitrypsin was 
named α1-PI (Travis, 1986), however its original name is still more commonly used in 
the human literature.  The important physiological role of α1-PI in the body became 
particularly evident when Laurell and Eriksson (1963) first described a state of 
deficiency of α1-antitrypsin in humans.  Patients with this condition develop progressive 
lung emphysema due to insufficient inhibition of neutrophil elastase, which subsequently 
degrades elastin in the alveoli. Alpha1-antitrypsin deficiency also has been associated 
with chronic liver disease in humans, which is likely related to accumulation of 
abnormal inhibitor protein within hepatocytes (Nemeth, 1994).  Alpha1-antitrypsin 
deficiency is now known to be one of the most frequent congenital disorders in humans 
(Graziadei et al., 1998). Mellor et al. (2006) have described a case of α1-PI deficiency 
and concurrent Bartonella infection in association with panniculitis, polyarthritis, and 
meningitis in a Cavalier King Charles Spaniel. To the authors’ knowledge, studies on 
abnormal or deficient α1-PI or associated syndromes have not been reported in cats. 
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Owing to its property of inhibiting proteinases, α1-PI escapes degradation in the 
gastrointestinal lumen, and its measurement in feces has been shown to be useful as a 
marker for gastrointestinal protein loss in both humans and dogs (Murphy et al., 2003; 
Karbach, 1983). In normal individuals, only minimal amounts of α1-PI are present in the 
gastrointestinal lumen. As α1-PI has a similar molecular mass and charge to albumin, α1-
PI tends to be lost into the gastrointestinal lumen whenever albumin leaks into the lumen 
as a result of increased mucosal leakage in disease states (Williams, 1996). As α1-PI 
remains essentially intact in the gastrointestinal lumen, it can be used as a marker of 
transmucosal protein loss (Williams, 1996).  An ELISA for the measurement of α1-PI 
concentrations in fecal matter was developed and validated for dogs (Melgarejo et al., 
1998), and shown to be useful in the detection of protein loss in dogs with chronic 
gastrointestinal disease (Murphy et al., 2003).  Fecal α1-PI concentration may also prove 
useful in the detection of gastrointestinal protein loss in cats. However, immunoassays 
for α1-PI are species-specific.  In a previous study, our group has purified feline α1-PI 
(fα1-PI) from serum of cats (Fetz et al., 2004). We further used radial immunodiffusion 
to evaluate cross-immunoreactivity of fα1-PI antigen and antiserum of cats, dogs, and 
humans.  In that study we were unable to demonstrate any immunologic cross-reactivity 
between these species (unpublished data, 2002). Thus, our group developed a species-
specific radioimmunoassay for the detection of fα1-PI in serum from cats (Fetz et al., 
2004), but further studies showed that this assay was not useful to accurately quantify 
fα1-PI in fecal matter of cats (unpublished data, 2004).  Therefore, the aim of the present 
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study was to develop and analytically validate an immunoassay, which could be utilized 
for measurement of fα1-PI in serum as well as fecal samples from cats.  
 
MATERIALS AND METHODS 
Purification of α1-PI from feline serum. Feline α1-PI was isolated from pooled 
feline serum samples using ammonium sulfate precipitation, anion-exchange, size-
exclusion, ceramic hydroxyapatite, and hydrophobic interaction chromatography, as 
previously described (Fetz et al., 2004). 
Production, purification, and biotinylation of antibodies. Polyclonal 
antibodies against fα1-PI were raised in two New Zealand White rabbits by repeated 
inoculation with 150 µg of pure fα1-PI emulsified in complete and incomplete Freund’s 
adjuvant using a commercial antibody production service (Lampire Biological 
Laboratories, Pipersville, Pennsylvania). The rabbit anti-fα1-PI antibodies were purified 
by affinity chromatography, using purified fα1-PI coupled to N-hydroxysuccinamide-
activated Sepharose (Amersham Biosciences Corp., Uppsala, Sweden).  Purified 
antibodies from the first rabbit were used as capture antibodies, while purified antibodies 
from the second rabbit were biotinylated using a commercially available kit (Pierce, 
Rockford, Illinois), and used as reporter antibodies. 
Collection of fecal and serum samples. Blood was collected from the jugular 
vein from 44 healthy cats owned by students and staff of the Veterinary Medical 
Teaching Hospital at Texas A&M University (VMTH-TAMU). This procedure was 
approved by the Clinical Research Review Committee (CRRC) at TAMU (#2005-27). 
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Information about breed or age of these cats was not available. Serum was separated and 
stored at -80ºC until required.  Fecal samples were collected from 20 cats (age range: 1-
16 years, median: 5.5 years; sex and sexual status: female spayed: 14, male neutered: 6; 
breeds: Domestic Short Hair: 11, Domestic Long Hair: 5, Domestic Medium Hair: 3, 
Norwegian Forest cat:  1) owned by staff and students of the VMTH-TAMU. This 
procedure was approved by the CRRC at TAMU (CRRC #2003-01).  One gram of 
naturally-passed fecal material was collected from each cat’s litter box once a day for 
three consecutive days, and placed in pre-weighed plastic tubes (Sarstedt, Nümbrecht, 
Germany).  All samples were frozen immediately and stored at -20ºC by the cat’s owner, 
and then stored at -80 ºC at the Gastrointestinal Laboratory.  
Extraction of fecal fα1-PI. The following protocol was used for the extraction of 
fα1-PI from feces and was modified from a procedure originally described by Melgarejo 
et al. (1998).  Each fecal sample was diluted 1:5 with phosphate-buffered saline (PBS), 
(Pierce, Rockford, Illinois), containing 5% newborn calf serum (NBCS), (Sigma-
Aldrich, Inc., St. Louis, Missouri), and 0.01% thimerosal (Sigma-Aldrich, Inc., St. 
Louis, Missouri), pH 7.3.  Each diluted fecal sample was homogenized using a mini 
vortexer (VWR, Suwanee, Georgia) for 20 minutes at room temperature.  The 
homogenized sample was then centrifuged (Beckman centrifuge GS-R6, GMI, Ramsey, 
Minnesota) at 3,800 g for 20 minutes at 4ºC.  The supernatant was removed using a tube 
filter (Fisher Scientific, Pittsburgh, Pennsylvania) and an aliquot of approximately 1.5 
ml was placed into a microcentrifuge tube (Fisher Scientific, Pittsburgh, Pennsylvania).  
The tube was then centrifuged at 10,000 g for 30 minutes (Eppendorf centrifuge 5417C, 
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Eppendorf, Hamburg, Germany) and the final supernatant was transferred into another 
microcentrifuge tube (Fisher Scientific, Pittsburgh, Pennsylvania) and stored at -20ºC 
until analysis.  For the ELISA, the processed fecal samples (1:5 dilution) were further 
diluted 1:400 with PBS, containing 5% NBCS and 0.01% thimerosal, pH 7.3, in order to 
reach a final dilution of 1:2,000. 
Preparation of standards. A 1 mg/ml solution of purified fα1-PI was diluted to 
concentrations of 4, 2, 1, 0.5, 0.25, 0.125, and 0.0625 µg/L, using PBS containing 5% 
NBCS and 0.01% thimerosal, pH 7.3. 
Enzyme-linked immunosorbent assay (ELISA). Each well of the microtiter 
plate (Thermo Electron Oy, Vantaa, Finland) was coated with 100 ng of purified capture 
antibodies diluted in 100 µl of 20 mM sodium carbonate bicarbonate buffer (Pierce, 
Rockford, Illinois), pH 9.6. The plate was incubated for one hour at 37ºC and then 
washed three times with PBS, containing 0.5% polyoxyethylenesorbitanmonolaurate 
(TWEEN-20, Sigma-Aldrich, Inc., St. Louis, Missouri). Next, 200 µl of SuperBlock® 
(Pierce, Rockford, Illinois) were added to each well in order to block nonspecific 
antibody binding sites. After incubation for one hour at 37ºC, the plate was again washed 
three times with PBS/TWEEN-20. One hundred µl of each of the seven standard 
solutions and 100 µl of the diluted fecal extracts or the diluted serum sample were added 
to the wells in duplicate and incubated for one hour at 37°C. For blanks the duplicate 
wells were loaded with 100 µl PBS, containing 5% NBCS and 0.01% thimerosal, pH 
7.3. After three washes with PBS/TWEEN-20, 50 ng of biotinylated antibodies in 100 
µL PBS containing 5% NBCS and 0.01% thimerosal, pH 7.3, were added to each well 
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and incubated for one hour at 37°C. The plate was again washed three times with 
PBS/TWEEN-20 and 5 ng of a streptavidin horseradish peroxidase (S-HRP) preparation 
(Sigma-Aldrich, Inc., St. Louis, Missouri) in 100 µL PBS containing 5% NBCS and 
0.01% thimerosal, pH 7.3 was added to each well. After 30 minutes of incubation at 
37ºC, the plate was once again washed three times with PBS/TWEEN 20 and a 
peroxidase substrate (TMB), (Pierce, Rockford, Illinois), was used to develop the plate. 
After eight minutes of incubation at room temperature, the reaction was stopped by 
adding 100 µl/well of a 4 M acetic acid, 0.5 M sulfuric acid solution. The microtiter 
plate was then read at 450 nm using an automated microplate reader and concentrations 
for fecal α1-PI were calculated using the manufacturer’s software (Labsystems Multiskan 
Ascent, Scientific Resources Southwest, Stafford, Texas). The standard curve was 
transformed in a log10/linear fashion and was based on a four parameter logistic fit 
using the formula y=b+(a-b)/(1+xc)d. 
Assay validation. The assay was validated by determination of the lowest 
detectable concentration, dilutional parallelism (linearity), spiking recovery of added α1-
PI (accuracy), and intra- and inter-assay coefficients of variation (reproducibility and 
precision, respectively). The validation procedures were performed separately for fecal 
extracts and serum samples. Statistical analyses were performed by commercially 
available software (GraphPad Prism 4, GraphPad Software Inc., San Diego, California).  
The lower detection limit was determined by setting up ten duplicates of samples 
with zero fα1-PI  (suspended in PBS containing 5% NBCSe and 0.01% thimerosal, pH 
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7.3), and calculating the concentration of α1-PI with an absorbance change equal to or 
greater than three standard deviations (SD) of these ten duplicates.  
Linearity of the assay was determined by dilutional parallelism. Three serum 
samples from different cats were analyzed at dilutions of 1:500,000, 1:1,000,000, 
1:2,000,000, 1:4,000,000, and 1:8,000,000. Three fecal samples from different cats were 
measured at dilutions of 1:1,000, 1:2,000, 1:4,000, and 1:8,000. The percentage of bias 
(in %) after each dilutional step was calculated from the observed to expected ratio. For 
this, the observed fα1-PI concentration (value measured by the assay) was divided by the 
expected fα1-PI concentration (value calculated according to the dilution factor), and 
multiplied by 100 (O/E x 100).  
Accuracy of the assay was tested by spiking three serum samples and three fecal 
extracts each with known concentrations of purified fα1-PI (2, 1, 0.5, 0.25, 0.125, 
0.0625, and 0.03125 µg/L). Standard recovery (in %) after each spiking step was 
calculated from the obtained fα1-PI concentration (value measured by the assay), divided 
by the expected fα1-PI concentration (value calculated based on the added concentration 
of α1-PI) and multiplied by 100 (O/E x 100). 
Precision of the assay was determined by evaluation of three serum samples and 
three fecal extracts ten times within the same assay on the same day (intra-assay 
variability).  
Reproducibility was determined by analyzing the same three serum samples and 
fecal extracts in ten consecutive assay runs (inter-assay variability). Reproducibility and 
precision were calculated as coefficient of variation (CV%= SD/ mean x 100%).  
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The reference interval for fα1-PI in serum was generated by calculating the 
central 95th percentile of 44 serum samples from healthy cats. The reference interval for 
fα1-PI in feces was established by evaluating the lower 97.5th percentile of the mean 
concentration of fα1-PI from three fecal samples collected on consecutive days from 
each of 20 healthy cats. Additionally, the mean coefficient of variation for the three fecal 
samples was calculated for this group of cats. Statistical significance was defined as P< 
0.05. 
 
RESULTS 
Standard curves for the fα1-PI ELISA (Figure 1) were reproducible.  
Lower detection limit. The lower detection limit of the assay was 0.02 g/L in 
serum and 0.04 µg/g in fecal samples.  
Linearity (dilutional parallelism). Observed to expected (O/E) ratios for five 
serial dilutions of three serum samples ranged from 100.0 to 129.7% (mean ±SD: 112.2 
±9.9%) (Table 1). O/E ratios for four serial dilutions of fecal extracts ranged from 
103.5% to 141.6% (mean ±SD: 115.6 ±12.8%) (Table 2).  
Accuracy (spiking recovery). O/E ratios for serum and fecal samples spiked 
with different concentrations of purified fα1-PI ranged from 82.3 to 107.8% (94.7 
±7.6%) for serum samples (Table 3), and 78.5% to 148.7% (96.8 ±18.2%) for fecal 
samples (Table 4).  
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Precision (intra-assay variability). Coefficients of variation for intra-assay 
variability were 4.9, 6.4, and 7.9% for serum samples (Table 5), and 5.3%, 11.8%, and 
14.2% for fecal samples (Table 6).  
Reproducibility (inter-assay variability). The coefficients of variation for inter-
assay variability were 6.8%, 10.0%, and 12.1% for serum samples (Table 5), and 7.7%, 
10.2%, and 20.4% for fecal samples (Table 6).  
Reference intervals. The reference interval for serum fα1-PI as determined by 
calculation of the central 95th percentile was 0.64 to 1.4 g/L. Fecal fα1-PI concentrations 
in all 60 samples from 20 healthy cats ranged from 0.04-1.9 µg/g, with a median of 0.42 
µg/g (Figure 2). The reference interval for fecal fα1-PI, as calculated by the lower 97.5th 
percentile for the average fα1-PI concentrations of three fecal samples for each cat, was 
0.04 to 1.6 µg/g of fecal material.  
Three-day-variation of fα1-PI concentrations for fecal extracts. The mean 
coefficient of variation for the three fecal samples was 46% (Figure 3). Lower mean α1-
PI concentrations had significantly higher coefficients of variation compared to higher 
mean α1-PI concentrations (P < 0.05; r2=0.206). 
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Table 1. Results for dilutional parallelism of serum samples for the feline α1-PI ELISA.  
All three serum samples (I-III) were evaluated at the dilutions of 1:500,000; 1:1,000,000; 
1:2,000,000; 1:4,000,000; and 1:8,000,000 and the observed (O) to expected (E) ratios 
were calculated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Dilution 
 
O 
g/L 
E 
g/L 
O/E 
% 
Serum I 500,000 2.96     
 1,000,000 1.61 1.48 108.78 
 2,000,000 0.80 0.74 108.11 
 4,000,000 0.43 0.37 116.22 
 8,000,000 0.23 0.19 121.05 
 
    
Serum II 500,000 1.09     
 1,000,000 0.56 0.55 101.82 
 2,000,000 0.28 0.27 103.70 
 4,000,000 0.14 0.14 100.00 
 8,000,000 0.07 0.07 100.00 
 
    
Serum III 500,000 2.02     
 1,000,000 1.31 1.01 129.70 
 2,000,000 0.60 0.51 117.65 
 4,000,000 0.31 0.25 124.00 
 8,000,000 0.15 0.13 115.38 
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Table 2. Results for dilutional parallelism of fecal extracts for the feline α1-PI ELISA.  
All three fecal samples (I-III) were evaluated at the dilutions 1:1,000; 1:2,000; 1:4,000; 
and 1:8,000 and the observed (O) to expected (E) ratios were calculated. 
 
  
 Dilution 
 
O  
(µg/g) 
E 
(µg/g) 
O/E 
(%) 
Feces I 1000 0.830     
 2000 0.460 0.415 110.84 
 4000 0.230 0.208 110.58 
 8000 0.110 0.104 105.77 
 
    
Feces II 1000 3.500     
 2000 2.010 1.750 114.86 
 4000 1.160 0.875 132.57 
 8000 0.620 0.438 141.55 
 
    
Feces III 1000 0.290     
 2000 0.150 0.145 103.45 
 4000 0.080 0.073 109.59 
 8000 0.040 0.036 111.11 
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Table 3. Results for spiking recovery of serum samples for the feline α1-PI ELISA. 
Seven different concentrations of feline α1-PI (2, 1, 0.5, 0.25, 0.125, 0.0625, and 0.03125 
g/L) were added to three different serum samples (I-III) and the observed (O) to 
expected (E) ratios were calculated. 
 
 
 
 
 
 
  
 Concentration 
added in g/L 
O 
g/L 
E 
g/L 
O/E 
% 
Serum I 0.0000 1.37     
 0.0315 1.50 1.40 107.14 
 0.0625 1.39 1.43 97.20 
 0.1250 1.40 1.50 93.33 
 0.2500 1.47 1.62 90.74 
 0.5000 1.74 1.87 93.05 
 1.0000 2.46 2.37 103.80 
 2.0000 2.92 3.37 86.65 
 
    
Serum II 0.0000 0.60     
 0.0315 0.60 0.63 95.24 
 0.0625 0.59 0.66 89.39 
 0.1250 0.66 0.73 90.41 
 0.2500 0.70 0.85 82.35 
 0.5000 0.94 1.10 85.45 
 1.0000 1.69 1.60 105.63 
 2.0000 2.14 2.60 82.31 
 
    
Serum III 0.0000 1.12     
 0.0315 1.24 1.15 107.83 
 0.0625 1.21 1.18 102.54 
 0.1250 1.22 1.25 97.60 
 0.2500 1.33 1.37 97.08 
 0.5000 1.53 1.62 94.44 
 1.0000 1.96 2.12 92.45 
 2.0000 2.93 3.12 93.91 
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Table 4. Results for spiking recovery of fecal extracts of the feline α1-PI ELISA. 
Seven different concentrations of feline α1-PI (2, 1, 0.5, 0.25, 0.125, 0.0625, and 0.03125 
µg/g) were added to three different fecal samples (I-III) and the observed (O) to 
expected (E) ratios were calculated. 
 
 
 
 
 
 
 
  
 Concentration 
added in µg/g 
O  
(µg/g) 
E 
(µg/g) 
O/E 
(%) 
Feces I 0.0000 0.44     
 
0.0315 0.56 0.47 119.15 
 
0.0625 0.57 0.50 114.00 
 
0.1250 0.56 0.56 99.12 
 
0.2500 0.75 0.69 108.70 
 
0.5000 0.83 0.94 88.30 
 
1.0000 1.20 1.44 83.33 
 
2.0000 2.01 2.44 82.38 
 
    
Feces II 0.0000 2.11     
 
0.0315 2.15 2.14 100.47 
 
0.0625 1.92 2.17 88.48 
 
0.1250 1.91 2.24 85.27 
 
0.2500 1.97 2.36 83.47 
 
0.5000 2.10 2.61 80.46 
 
1.0000 2.44 3.11 78.46 
 
2.0000 3.41 4.11 82.97 
 
    
Feces III 0.0000 0.12     
 0.0315 0.14 0.15 93.33 
 0.0625 0.19 0.18 105.56 
 0.1250 0.32 0.25 128.00 
 0.2500 0.55 0.37 148.65 
 0.5000 0.53 0.62 85.48 
 1.0000 0.97 1.12 86.61 
 2.0000 1.90 2.12 89.62 
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Table 5. Precision and reproducibility of serum samples for the feline α1-PI ELISA. 
This table shows coefficients of variation (CV) for three different serum samples (S I-
III) for the intra-assay and inter-assay variability of the feline α1-PI ELISA. Serum 
samples were evaluated ten times within the same assay run (intra-assay) and ten times 
in consecutive runs (inter-assay). 
 
 
 
 
 
 Number 
of repeats 
Mean 
(g/L) 
Standard 
deviation 
(g/L) 
Coefficient 
of variation 
(%) 
Intra-assay 
variability 
    
 S I 10 0.56 0.03 4.9 
S II 10 1.14 0.07 6.4 
S III 10 1.45 0.11 7.9 
Inter-assay 
variability 
    
S I 10 0.54 0.04 6.8 
S II 10 1.07 0.11 10.0 
S III 10 1.44 0.17 12.1 
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Table 6. Precision and reproducibility of fecal extracts for the feline α1-PI ELISA. 
This table shows coefficients of variation (CV) for three different fecal extracts (F I-III) 
for the intra-assay and inter-assay variability of the feline α1-PI ELISA. Fecal extracts 
were evaluated ten times within the same assay run (intra-assay) and ten times in 
consecutive runs (inter-assay). 
 
 
 Number 
of repeats 
Mean 
(µg/g) 
Standard 
deviation 
(µg/g) 
Coefficient 
of variation 
(%) 
Intra-assay 
variability 
    
F I 10 0.110 0.016 14.2 
F II 10 0.387 0.045 11.8 
F III 10 1.997 0.107 5.3 
Inter-assay 
variability 
    
F I 10 0.119 0.024 20.4 
F II 10 0.442 0.034 7.7 
F III 10 1.925 0.196 10.2 
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Figure 1. Representative standard curve for the feline α1–PI ELISA. The curve is based 
on a four parameter logistic fit curve [y=b+(a-b)/(1+xc)d] transformed in a log10/linear 
fashion. The seven standards had the following concentrations: 4, 2, 1, 0.5, 0.25, 0.125, 
and 0.0625 µg/L.  
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Figure 2. Variation of fecal α1–PI concentrations in three fecal samples of 20 healthy 
cats. This figure shows the day to day variation of fecal α1-PI concentrations of the three 
fecal samples collected from each of 20 healthy cats on consecutive days. Cats no. 3, 8, 
and 20 had one fecal sample each with a concentration in the undetectable range, 
designated here as a concentration equal to the lower range of detection of 0.04 µg/g. 
The coefficient of variation for the three fecal samples was significantly higher in 
samples with lower mean α1-PI concentrations (P< 0.05; r2=0.206), while the mean 
coefficient of variation for all 20 cats was 46%.  
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Figure 3. Mean fecal α1–PI concentrations in healthy cats. This figure illustrates the 
mean fecal α1-PI concentrations of the 3 fecal samples collected each from 20 healthy 
cats. The median of the mean fecal α1-PI concentrations of the 20 healthy control cats 
was 0.42 µg/g of fecal material as shown as the straight line in the figure. The dotted line 
in this figure shows the upper limit of reference interval (1.6 µg/g). 
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DISCUSSION 
An ELISA for the quantification of fα1-PI in serum and feces from cats was 
successfully developed. In contrast to the previously developed radioimmunoassay, the 
ELISA also has sufficient analytical performance to measure fα1-PI in fecal samples, 
and, to the authors’ knowledge, represents the first assay available for this purpose.  
Alpha1-PI is the prototype of the serine proteinase inhibitors, a family of proteins 
known to be very abundant in mammalian plasma (Hibbetts et al, 1999). Although 
determined with different analytical methods, the reference interval for serum α1-PI 
established for cats in our study (0.64-1.4 g/L) was comparable to reference intervals of 
other species, e.g., humans (1.1-2.1 g/L) (Ward et al. 1985), dogs (0.9-2.11 g/L) 
(Melgarejo et al. 1998), or horses (1.3-1.6 g/L) (Patterson et al., 1991). Because of the 
relative abundance of α1-PI in blood, it was necessary to greatly dilute serum samples 
from healthy cats (e.g., 1:1,000,000), in order to be able to measure its concentration 
within the range of standards for our assay (0.0625 to 4 µg/L). In contrast, the 
concentration of α1-PI in feces is only a fraction of that in serum in healthy cats, and 
therefore, dilutions of fecal samples for our assay were much lower compared to serum 
samples (e.g., 1:2000). 
The lower detection limit of the assay was determined to be 0.02 g/L for serum 
samples, which appears to be an acceptable value considering the established reference 
interval for serum samples of 0.64-1.4 g/L. This newly established reference interval for 
serum samples from 44 healthy cats is slightly higher, but comparable to the previously 
established reference interval for serum α1-PI concentrations of 0.25 to 0.6 g/L based on 
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a radioimmunoassay using a different group of 50 healthy cats (Fetz et al., 2004). 
Differences between these reference intervals are readily explained by the different 
methodologies for the two immunoassays. 
Given that fecal samples were extracted from grams of fecal matter, the unit µg/g 
was chosen for expressing the concentration of α1-PI in fecal extracts. Compared to 
serum samples and considering the different unit, the lower detection limit of the assay 
for fecal extracts was similarly low at 0.04 µg/g. As expected, the concentration of α1-PI 
in fecal extracts was occasionally below the value of the lower limit of detection in a few 
of the healthy cats, and these values were therefore defined as <0.04 µg/g.   
The measurement of fecal α1-PI concentrations in healthy cats resulted in the 
establishment of a relatively narrow control range (<0.04-1.6 µg/g). Fecal α1-PI 
concentrations in healthy cats were lower compared to the control range of fecal α1-PI 
concentrations previously established in dogs (0.23 to 5.67 µg/g). While the canine assay 
is also an ELISA, discrepancies in reference intervals may be explained by differences 
of assay properties. Alternatively, this may suggest differences in the physiological 
distribution of α1-PI in these two species. Heilmann et al. (2011) recently developed and 
analytically validated a radioimmunoassay (RIA) for fecal canine α1-PI. This assay 
agreed well with the previously established ELISA for this species.  
Dilutional parallelism studies are useful to demonstrate the relative recovery after 
dilution and thus the linearity of the assay. Observed to expected ratios for dilutional 
parallelism for serum and fecal samples had a mean ±SD of 112.2% ± 9.9 and 115.6% ± 
12.8, respectively. While 100% is the ideal value, our results revealed acceptable, slight 
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over-recovery on dilution of both serum and fecal samples. The reason for the over-
recovery in our assay is not clear, but this may be generally explained by the presence of 
high-affinity antibodies (Crowther, 2001).  
Accuracy, representing the ability of an assay to measure the true value of an 
analyte, is tested by spiking recovery. Both negative and positive biases were noted over 
the range of serum and fecal samples, likely indicating the presence of both proportional 
and constant biases. Furthermore, for both sample types, there appears to be a tendency 
for a negative bias when higher α1-PI concentrations are added. While the degree of bias 
is more pronounced with fecal extracts compared to serum samples, the overall mean 
bias and SD of 94.7 ±7.6 for serum samples and 96.8 ±18.2 for fecal samples appear 
acceptable. 
Precision and reproducibility may be considered as the most important technical 
aspects of an immunoassay (Deshpande, 1996). Intra- and inter-assay coefficients of 
variation (CV) of equal to or less than 15% indicate adequate precision and 
reproducibility for acceptable assay performance for clinical use of an assay (Crowther, 
2001). An assay’s CV will typically vary with the analyte’s concentration, with higher 
CV values often found at the lower and upper limits of the analytical range of the assay 
(Stockham and Scott, 2008). The validation of our assay revealed greater precision and 
reproducibility for lower fα1-PI concentrations in serum. In contrast, fecal extracts 
showed greater precision and reproducibility at higher fα1-PI concentrations.  Precision 
especially decreased for the lowest fecal fα1-PI concentrations for both intra-and 
interassay runs (CV% 14.2 and 20.4, respectively). While potential concern from these 
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values for appropriate assay precision in low concentration samples cannot be denied, 
impact on the clinical utility of the assay may not be as great because protein-losing 
enteropathies are expected to cause elevated concentrations of this protein in feces, 
where assay precision is acceptable.   
We further showed that fα1-PI concentrations in feces can vary significantly in 
healthy cats in consecutive samples of the same individual (mean coefficient of 
variation: 46%). The large coefficients of variation suggests that more than one fecal 
sample should be collected in order to increase the accuracy in future clinical studies 
regarding gastrointestinal loss of this protein.  
An important limit of this study is the low number of the reference sample group 
for both fecal and serum samples. For our study, 44 serum and 60 fecal samples (the 
latter consisting of three samples from 20 individual cats each) were available at the time 
of the assay validation. Based on statistical recommendations, reference intervals should 
be established from at least 120 independent observations; however, if a Gaussian 
distribution is present, as was the case for our samples, a minimum of 60 samples from 
qualified individuals is generally regarded as sufficient (Lumsden, 2000). As reduced 
number of individuals may lead to lower statistical power to detect significant 
differences between healthy and diseased animals, the establishment of a new reference 
interval based on serum and fecal samples from at least 60 individuals is needed when 
conducting the clinical evaluation of this assay. Furthermore, we did not perform studies 
on the effect of storage or repeated freeze-thaw cycles on recovery of fα1-PI. Preliminary 
studies have shown that purified fα1-PI appears to be stable for >3 years when stored at -
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80ºC. However, studies regarding stability of this protein in serum, feces or fecal 
extracts at more commonly used storage temperatures are still warranted.  
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CHAPTER III 
 
EVALUATION OF FECAL ALPHA1-PROTEINASE INHIBITOR 
CONCENTRATIONS IN CATS WITH IDIOPATHIC INFLAMMATORY 
BOWEL DISEASE AND CATS WITH GASTROINTESTINAL NEOPLASIA 
 
OVERVIEW 
Idiopathic inflammatory bowel disease (IBD) and gastrointestinal (GI) 
lymphoma are common disorders in cats. The aim of this study was to evaluate fecal α1-
PI concentrations, a marker of GI protein loss, in cats with histopathological evidence of 
GI inflammation or GI neoplasia. 
Twenty cats with clinical signs of chronic GI disease and 20 healthy control cats 
were enrolled. Diagnostic endoscopies with histopathological evaluation were performed 
on the 20 diseased cats. Two groups of cats were assembled [Group A (n=8): mild to 
moderate IBD, Group B (n=12): severe IBD or neoplastic disease].  Fecal α1-PI 
concentrations and serum concentrations of total protein, albumin, globulin, cobalamin, 
folate, pancreatic lipase immunoreactivity, and trypsin-like immunoreactivity were 
determined. 
Nineteen of the 20 diseased cats had elevated fecal α1-PI concentrations, ranging 
from 1.9 to 233.6 µg/g (normal range: ≤1.6 µg/g). Fecal α1-PI concentrations were 
statistically significantly different between healthy cats and cats of Group A (median: 
3.9 µg/g, range: 1.3 to 9.2 µg/g, P<0.001) or cats of Group B (median: 20.6 µg/g, 4.3 to 
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233.6 µg/g; P<0.001), and between cats of Groups A and B (P<0.01). 
Hypoalbuminemia, hypoproteinemia, and hypocobalaminemia were detected in 88%, 
83%, and 56% of the diseased cats, respectively. 
This study suggests that increased fecal α1-PI concentrations in association with 
low serum albumin and total protein concentrations may be a common finding in cats 
with IBD or GI neoplasia. Furthermore, α1-PI concentrations appear to be higher in cats 
with severe IBD or confirmed GI neoplasia when compared to cats with mild to 
moderate IBD. 
 
INTRODUCTION 
Idiopathic inflammatory bowel disease (IBD) and gastrointestinal (GI) 
lymphoma are commonly diagnosed disorders in cats with chronic clinical signs of GI 
disease. Idiopathic inflammatory bowel disease refers to a group of poorly understood 
chronic gastroenteropathies that are characterized by infiltration of the GI mucosa with 
inflammatory cells. Infiltrating inflammatory cells most commonly consist of 
lymphocytes and/or plasma cells, while additional infiltrates of neutrophils, histiocytes, 
and eosinophils also may be observed (Wilcock, 1992; Waly et al., 2004) The 
etiopathogenesis of IBD in cats remains largely unclear, but it is thought to be related to 
complex interactions between host susceptibility, mucosal immunity, and the enteric 
microbiota (Jergens et al., 1992). 
Gastrointestinal lymphoma is considered one of the most commonly diagnosed 
neoplasms in cats and its prevalence has increased significantly in the past two decades 
    
 
33
(Wilson, 2008). Clinical signs of both IBD and GI lymphoma are non-specific, and 
commonly include vomiting, diarrhea, weight loss, anorexia, or any combination of 
these signs. The diagnosis of IBD or GI lymphoma is generally made by excluding other 
GI disorders with similar clinical signs, such as dietary hypersensitivity, 
hyperthyroidism, parasitism, or hepatic, pancreatic, or renal disease, and histopathologic 
evaluation of intestinal biopsy samples.  
In dogs, IBD, GI lymphoma, or any other chronic gastroenteropathy producing 
inflammation, vascular congestion, or bleeding may be associated with transmucosal 
loss of plasma proteins, protein malabsorption, or both (Murphy et al., 2003). In protein-
losing gastroenteropathies (PLE), GI disease results in nonselective protein loss. 
Clinicians may only recognize severe cases of PLE, when GI protein loss has exceeded 
albumin production by the liver, thus leading to hypoalbuminemia or a decreased serum 
total protein concentration. In the veterinary literature there has been little mention of 
protein loss associated with gastroenteropathies in cats. This may reflect the difficulties 
in diagnosing GI protein loss in this species due to the lack of suitable diagnostic 
methods, or the failure to recognize the presence of this condition in cats until other, 
more severe manifestations of their GI disease are observed.  
Gastrointestinal protein loss in humans and dogs can be diagnosed by the 
measurement of the endogenous protein α1-proteinase inhibitor (α1-PI) in feces (Thomas 
et al., 1981; Karbach et al., 1983; Murphy et al., 2003). In healthy individuals, only 
minute amounts of α1-PI are present in the gastrointestinal lumen. Like other plasma 
proteins, α1-PI may be lost into the GI lumen as a result of gastrointestinal disease. 
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Unlike most other plasma proteins, including albumin, α1-PI is a proteinase inhibitor and 
thus able to resist degradation by digestive or bacterial proteolytic enzymes and 
therefore can be detected in feces by use of an immunoassay (Suchodolski and Steiner, 
2003).  
We have recently reported on the development and analytical validation of an 
ELISA for the measurement of α1-PI concentrations in fecal samples of cats (Burke et 
al., 2012). The aim of this study was to evaluate fecal α1-PI concentrations in cats with a 
histopathological diagnosis of GI inflammation or cats with GI neoplasia. We 
hypothesize that fecal α1-PI concentrations would be higher in cats with chronic GI 
disease compared to healthy cats.  
 
MATERIALS AND METHODS 
Cats and sample collection. For the control group, 20 healthy cats owned by 
staff and students of the College of Veterinary Medicine and Biomedical Sciences at 
Texas A&M University were enrolled. From each cat one gram of naturally-passed fecal 
material was collected out of the litter box at home and placed in a pre-weighed plastic 
tube.  All samples were frozen immediately at -20ºC by the cat’s owner and then stored 
at -80 ºC at the Gastrointestinal Laboratory. Sera were not available from these cats. 
For the diseased group, a total of 20 cats with signs of chronic GI disease (>6 
weeks duration) were entered into the study. All cats were owned by clients of the 
Animal Medical Center (AMC) in New York City and recruited for an unrelated study. 
All cats exhibited various combinations of clinical signs, such as vomiting, diarrhea, 
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weight loss, and anorexia at the time of initial presentation (Table 1).  Diagnostic tests 
evaluated in these cats included complete blood count, serum biochemistry profile, 
urinalysis, fecal direct smear and flotation, serum total T4, and FeLV/ FIV testing. None 
of the cats was on any treatments for at least three weeks before enrollment. After 
enrollment approximately one to two grams of naturally-passed fecal material and one 
blood sample were collected from each cat. Serum was obtained from the blood samples. 
Both fecal and serum samples were frozen immediately and kept at -80 ºC until they 
were shipped frozen to the Gastrointestinal Laboratory at Texas A&M University.  
Biopsy procedure and histopathological examination. All cats of the diseased 
group underwent gastroduodenoscopy in order to obtain gastric and intestinal biopsies. 
Three cats also underwent colonoscopy in order to obtain colonic biopsies. From two 
cats, liver biopsies were obtained percutaneously under ultrasound-guidance using a 
disposable 18 gauge tru-cut biopsy needle (Bard Biopsy Systems, Tempe, AZ).  
Cats were premedicated with glycopyrrolate (0.01 mg/kg, IM) or atropine (0.02 mg/kg, 
IM). Anesthesia was induced with propofol (3 to 6 mg/kg, IV) and diazepam (0.5 mg/kg, 
IV), and maintained with inhaled isoflurane or sevoflurane and oxygen. 
Gastroduodenoscopy and colonoscopy were performed by a single endoscopist. A video 
gastroscope (GIF 100, Olympus America, Mellville, NY) with a 100-cm insertion tube, 
9.5-mm outer diameter, and a 2.8-mm working channel as well as a 2.6-mm flexible 
biopsy forceps were used. Mucosal surfaces were evaluated and gross lesions were 
recorded. Multiple representative specimens were obtained for histological evaluation in 
each cat. 
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Biopsy specimens were labeled and placed in jars containing 10% formalin 
solution and submitted for histopathological evaluation. The histopathological evaluation 
was performed by one of four pathologists. Specimens were evaluated for inflammatory, 
neoplastic, or other lesions. Idiopathic inflammatory bowel disease was diagnosed based 
on varying degrees of infiltration by inflammatory cells (mainly mixed populations of 
lymphocytes and plasma cells, and small, mature lymphocytes being most prominent) 
within the mucosa and submucosa without any identifiable underlying cause for the 
inflammatory infiltrate. Histopathological grading was performed as described by Hart et 
al. (1994). Mild grade consists of mild to moderate diffuse infiltration of the mucosa 
with inflammatory cells with no architectural changes. Moderate grade consisted of 
moderate diffuse infiltration of the mucosa with inflammatory cells, mild to moderate 
edema or fibrosis of the mucosa, slight villus blunting with irregular crypts, and 
occasional dilated lacteals. Severe grade consisted of severe diffuse infiltration of the 
mucosa with inflammatory cells, variable epithelial flattening and erosion, moderate to 
severe edema and fibrosis, fusion and blunting of villi and dilated lacteals, crypt 
hyperplasia, and crypt abscessation. Gastrointestinal lymphoma was diagnosed based on 
marked mucosal infiltration and expansion by a mainly monomorphic population of 
lymphoid cells with much fewer other inflammatory cells present. Based on the results 
of the histopathologic examination, cats were classified into the following two groups: 
Group A included cats with mild or moderate enteritis (histologic grade 1, HG 1) and 
Group B were cats with a HG >1, which included the following diagnoses: severe 
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enteritis (HG 2), an inconclusive diagnosis of either severe enteritis or GI lymphoma 
(HG 2-3), or definite diagnosis of GI lymphoma or other GI neoplasia (HG 3).  
Fecal and serum assays. Fecal α1-PI concentrations were measured in the feces 
from each cat with a previously developed and validated sandwich-ELISA (Burke et al., 
2011). A reference interval for feline α1-PI in feces was calculated by evaluating the 
lower 97.5th percentile of feline α1-PI concentration from fecal samples collected from 
the 20 healthy cats. Serum samples were available from 18 of the 20 diseased cats (11/12 
of Group A, and 7/8 of Group B).  Serum total protein, albumin, and globulin 
concentrations were measured with a Hitachi 911 (Diamonds Diagnostics, Holliston, 
MA, USA), at the Texas Veterinary Medical Diagnostic Laboratory, College Station, 
Texas. Serum concentrations for pancreatic lipase immunoreactivity (PLI), and trypsin-
like immunoreactivity (TLI) were measured by in-house-ELISA and in-house RIA, 
respectively. Serum cobalamin and folate were measured using an Immulite 2000 
(Siemens Healthcare Diagnostic Inc., Tarrytown, NY, USA). Other clinicopathological 
findings were not available. 
Statistical evaluation. Commercially available software (GraphPad Prism 4, 
Graph Pad, San Diego, California) was used for all statistical analyses. Data were tested 
for normal distribution with the D’Agostino and Pearson omnibus test. Fecal α1-PI 
concentrations were transformed to log10 values for normal distribution and compared 
between healthy cats, cats of Group A, and cats of Group B with a 1-way ANOVA test, 
followed by Tukey’s multiple comparison tests. Serum concentrations for total protein, 
albumin, globulin, cobalamin, folate, PLI, and TLI were compared between cats of 
    
 
38
Group A and cats of Group B with a Mann-Whitney test. For all statistical analyses, 
statistical significance was defined as P< 0.05. 
 
RESULTS 
Signalment of healthy cats. Age range: 1-16 years (median: 5.5 years); sex and 
sexual status: female spayed: 14, male neutered: 6; breeds: Domestic Short Hair: 11, 
Domestic Long Hair: 5, Domestic Medium Hair: 3, Norwegian Forest cat:  1.  
Signalment of diseased cats. Ages of cats in Group A ranged from 4 to 17 years 
(median: 9 years), all cats were Domestic Shorthair cats (DSH), 5 cats were male 
neutered and 3 cats were female spayed (Table 7). Ages of cats in Group B ranged from 
4 to 16 years (median: 10 years), 5 were male neutered and 7 female spayed, 10 DSH, 1 
American Shorthair, 1 Maine Coon (Table 7). 
Clinical signs. The most common presenting clinical sign in both groups was 
weight loss (18/20; 90%), followed by diarrhea (15/20; 75%), vomiting (14/20; 70%), 
and anorexia (4/20; 20%). Most cats had multiple clinical signs and the most commonly 
reported combination of clinical signs for both groups was vomiting, diarrhea, and 
weight loss (7/20; 35%) (Table 7). The frequency of clinical signs for cats in Group A 
was: weight loss (7/8, 88%), vomiting (6/8, 75%), diarrhea (5/8, 63%), anorexia (1/8, 
13%). The frequency of clinical signs for cats in Group B was: weight loss (11/12, 92%), 
diarrhea (10/12, 83%), vomiting (9/12, 75%), anorexia (3/12, 25%). 
Histopathological and clinical diagnoses. Histopathological grading, lesion 
localization, and histopathological diagnoses of the cats with chronic GI disease are 
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shown in Table 8. Of the 20 diseased cats, a total of 8 cats were diagnosed with mild or 
moderate IBD and included in Group A (mild, n=3; mild to moderate, n=4; moderate, 
n=1) based on results of the histopathological examination. The remaining 12 cats were 
included in Group B and had the following diagnoses: severe IBD (n=2), inconclusive 
diagnosis of either severe IBD or GI lymphoma (n=5), confirmed GI neoplasia (n=5, 
including GI lymphoma, n=3; colonic carcinoma, n=2).  
Fecal α1-PI concentrations. In the healthy cats, fecal α1-PI concentrations 
ranged from 0.04 (or undetectable value) to 1.72 µg/g (median: 0.51 µg/g). The 
reference interval based on the lower 97.5th percentile was calculated to be ≤ 1.6 µg/g. 
Of the 20 diseased cats, 19 cats had increased fecal α1-PI concentrations (median: 7.5 
µg/g, range: 1.9 to 233.6), while one cat had fecal α1-PI concentrations (1.3 µg/g) within 
the reference interval of the healthy control cats (≤ 1.6 µg/g) (Table 7). Both cats of 
Group A (median: 3.9 µg/g, range: 1.3 to 9.2 µg/g) and those of Group B (median: 20.6 
µg/g, range: 4.3 to 233.6 µg/g) had statistically significant different fecal α1-PI 
concentrations compared to healthy cats (Tukey’s multiple comparison test; P<0.001 and 
P<0.001, respectively) (Figure 4). Also, fecal α1-PI concentrations were statistically 
significant different between Group A and B (Tukey’s multiple comparison test; 
P<0.01). When the two extreme values of cats in Group B (B-1: 233.6 µg/g, B-4: 179.2 
µg/g) were excluded before statistical evaluation, statistical significance persisted 
(Healthy cats vs. Group A, P<0.001; Healthy cats vs. Group B, P <0.001; Group A vs 
Group B, P<0.05).  
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Serum total protein concentrations. Serum total protein concentrations for both 
diseased groups ranged from 4.1 to 6.8 g/dL (median: 5.6 g/dL, reference interval: 6.5-
8.9 g/dL) (Table 7). Median serum total protein concentration was 6.2 g/dL (range: 4.4-
6.8 g/dL) for Group A and 5.2 g/dL (range: 4.1-6.2 g/dL) for Group B. Serum total 
protein concentrations were statistically significantly different from each other (Mann-
Whitney; P=0.0297). Hypoproteinemia was present in 15 of 18 cats (all: 83%; Group A: 
4/7, 57%; Group B: 11/11, 100%).  
Serum albumin concentrations. Serum albumin concentrations for both 
diseased groups ranged from 1.6-3.3 g/dL (median: 2.65 g/dL; reference interval: 3.2-4.7 
g/dL) (Table 7). Median serum albumin concentrations were 2.6 g/dL (range: 2.4-3.3 
g/dL) for Group A and 2.7 g/dL (range: 1.6-3.0 g/dL) for Group B. However, there was 
no statistical significance of serum albumin concentrations between cats of Groups A 
and B (P= 0.496). Hypoalbuminemia was present in 16 of 18 cats (88%; Group A: 5/7, 
71%; Group B: 11/11, 100%) 
Serum globulin concentrations. Serum globulin concentrations for both 
diseased groups ranged from 2.0-4.1 g/dL (median: 2.5 g/dL; reference interval: 2.8-4.8 
g/dL) (Table 7). Median serum globulin concentration was 3.5 g/dL (range: 2.0-4.1 
g/dL) for Group A and 2.5 g/dL (range: 2.1-3.6 g/dL) for Group B. Serum globulin 
concentrations were not statistically significantly different between both groups (Mann-
Whitney; P=0.0632). Hypoglobulinemia was present in 7 of 18 cats (38.8%; Group A: 
1/7, 14%; Group B: 6/11, 55%). Concurrent hypoalbuminemia was present in all cases 
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of hypoglobulinemia (panhypoproteinemia, 38.8%; Group A: 1/7, 14%; Group B: 6/11, 
55%). 
Serum cobalamin and folate concentrations. Hypocobalaminemia (<290 ng/L) 
was present in 10 of 18 cats (56%; Group A: 1/7, 14%; Group B: 9/11, 81%) (Table 9). 
In Group B, all cats with a diagnosis of severe IBD, severe IBD or GI lymphoma, or GI 
lymphoma were hypocobalaminemic, while the two cats with colonic carcinoma had 
cobalamin concentrations within the reference interval (290-1500 ng/L). Cobalamin 
concentrations of Group B cats (median: 139 ng/L, range: 99-1201 ng/L) were 
significantly lower than for cats of Group A (median: 994 ng/L, range: 153-1201 ng/L; 
Mann-Whitney; P=0.0098). Serum folate concentration was increased in two cats from 
Group A, decreased in one cat from Group B, and within the reference interval in the 
remaining cats. No statistically significant difference was observed for serum folate 
concentration between the two groups (Mann-Whitney, P=0.4688). 
Serum trypsin-like immunoreactivity (TLI) and serum pancreatic lipase 
immunoreactivity (PLI)) concentrations. Serum TLI concentrations ranged from 29.1 
to 206.7 µg/L (median: 84.7 µg/L; reference interval: 12-82 µg/L) in both groups (Group 
A: median: 72.7 µg/L, range: 47.9 - 145.9 µg/L; Group B: median: 102.3 µg/L, range: 
29.1-206.7 µg/L) (Table 9). Serum TLI concentration was increased in 9 of 18 cats 
(50%) of all diseased cats. More specifically, TLI was increased in 2 of 7 cats (29%) of 
Group A, and 7 of 11 cats of Group B (64%). No statistically significant difference was 
reached for serum TLI concentrations between the two groups (Mann Whitney, 
P=0.5261). 
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Serum PLI concentrations ranged from <2 to 54.8 µg/L (median: 6.1 µg/L; 
reference interval: 2-6.8 µg/L) in both groups (Group A: median: 4.8 µg/L, range: <2 to 
8.1 µg/L; Group B: median 6.1 µg/L, range: 3.7 to 54.8 µg/L,). Serum PLI concentration 
was increased in 7 of 18 cats (39%) of both groups, which included 2 cats (29%) of 
Group A, and 5 cats (45%) of Group B. The serum PLI concentration was strongly 
suggestive of pancreatitis (>12 µg/L) in 3 cats of Group B. No statistically significant 
difference was reached for serum PLI concentrations between the two groups (Mann 
Whitney, P=0.1451). 
Concurrent increases in serum TLI and PLI was present in 6 of 11 cats from both 
groups [Group A: 1/7; Group B: 5/11]. Increased TLI concentration without concurrent 
increase of the PLI concentration was present in 3 cats, while a mildly increased PLI 
concentration without concurrent increased TLI concentration was noted in one cat. 
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Table 7. Signalment, clinical signs, and serum concentrations of albumin, globulin, total protein, and fecal α1-PI 
concentrations of the cats with chronic GI disease. 
 
Cat ID Age (years) Sex Breed
Clinical 
signs
Total Protein 
(g/dL)
Albumin 
(g/dL)
Globulin 
(g/dL)
Fecal α1-PI 
(µg/g feces)
    
ref: 6.5-8.9 
g/dL
ref: 3.2-4.7 
g/dL
ref: 2.8-4.8 
g/dL
ref: ≤1.6 
µg/g)
GROUP A                
A-1 8 MN DSH VDW 6.5 3.3 3.2 1.9 
A-2 7 MN DSH VDW 6.1 2.6 3.5 9.2 
A-3 5 MN DSH VW 4.4 2.4 2.0 3.6 
A-4 10 MN DSH V 6.0 2.8 3.2 6.1 
A-5 4 FS DSH DW 6.2 2.4 3.8 1.3 
A-6 12 FS DSH VWA 6.6 2.5 4.1 2.6 
A-7 17 FS DSH VDW 6.8 3.2 3.6 4.2 
A-8 11 MN DSH DW NA NA NA 7.2 
GROUP B                
B-1 9 FS DSH VDWA 4.8 2.7 2.1 233.6 
B-2 10 MN DSH VDWA 5.7 2.8 3.1 4.3 
B-3 15 MN DSH VWA 6.2 3 3.2 7.7 
B-4 12 MN DSH W 4.4 2.1 2.3 179.2 
B-5 9 FS DSH VD 5.2 2.9 2.3 6.9 
B-6 11 MN DSH VDW NA NA NA 9.8 
B-7 16 FS DSH VDW 4.1 1.9 2.2 5 
B-8 10 FS ASH VDW 4.1 1.6 2.5 27.7 
B-9 8 FS DSH DW 5.4 2.1 3.3 14.2 
B-10 4 FS DSH VDW 4.7 2.6 2.1 30.8 
B-11 11 MN MNC VDW 5.5 2.7 2.8 27 
B-12 9 FS DSH DW 6.4 2.8 3.6 27.1 
 
Values outside of the reference interval are presented in bold and italic. MN, male neutered; FS, female spayed; DSH, Domestic Short Hair;  
ASH, American Short Hair; MNC, Maine Coon; V, vomiting; D, diarrhea; W, weight loss; A, anorexia; NA, not available  
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Table 8. Histopathological grading, lesion localization, and histopathological diagnoses of the cats with chronic GI disease. 
 
Clinically most significant diagnoses are indicated in bold. *HG, histopathologic grade: 1, mild to moderate inflammation; 2, severe inflammation;  
2 or 3, severe inflammation or neoplasm (inconclusive); 3, neoplasm. **g, gastrum; d, duodenum; c, colon; numbers correspond to the description  
of the histopathologic grade (see above). 
Cat ID HG* Lesion  Morphologic diagnosis of endoscopic biopsy specimens 
  
 localization**  
GROUP A       
A-1 1 g1, d1 Minimal lymphocytic  gastritis; mild lymphoplasmacytic enteritis  
A-2 1 g1, d1 Mild chronic gastritis; mild to moderate lymphoplasmacytic enteritis  
A-3 1 g1, d1 Mild lymphocytic gastritis with helical bacteria; mild lymphoplasmacytic enteritis 
A-4 1 g1, d1 Minimal lymphocytic  gastritis; mild lymphoplasmacytic enteritis 
A-5 1 g1, c1 Mild to moderate chronic lymphocytic gastritis; moderate  lymphoplasmacytic colitis, severe 
chronic cholangiohepatitis/portal hepatitis 
         A-6 1 g1, d1 Minimal lymphocytic gastritis with helical bacteria; mild to moderate plasmacytic enteritis 
A-7 1 g1, d1 Mild chronic gastritis; mild enteritis  
A-8 1 g1, d1 Mild gastritis; moderate lymphoplasmacytic enteritis, mild hepatic vacuolar degeneration 
GROUP B       
B-1 2 g1, d2 Mild gastritis with helical bacteria; severe lymphoplasmacytic enteritis 
B-2 2 g1, d2 Multifocal lymphocytic gastritis; severe lymphocytic enteritis  
B-3 2 or 3 g1, d2-3 Moderate lymphocytic gastritis with surface helical bacteria; severe diffuse lymphocytic 
enteritis or lymphoma 
B-4 2 or 3 g1, d2-3 Chronic moderate lymphocytic gastritis with helical bacteria; severe diffuse lymphocytic 
enteritis or lymphoma 
B-5 2 or 3 g1, d2-3 Minimal lymphocytic gastritis; severe diffuse enteritis/ suspect lymphoma  
B-6 2 or 3 g2-3, d2-3, c2-3 Severe gastroenteritis or lymphoma 
B-7 2 or 3 g1, d2-3 Mild chronic gastritis; severe gastroenteritis or lymphoma 
B-8 3 g3, d3 Gastric and duodenal lymphoma  
B-9 3 d3 Duodenal lymphoma 
B-10 3 g1, d3 Mild lymphocytic gastritis; duodenal lymphoma 
B-11 3 g2, d1, c3 Severe chronic active ulcerative lymphoplasmacytic gastritis with helical bacteria, mild 
lymphoplasmacytic enteritis; colonic adenocarcinoma 
B-12 3 g1, d1, c3 Mild gastritis; moderate lymphoplasmacytic proximal enteritis; severe diffuse lymphocytic distal 
enteritis; colonic carcinoma 
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Table 9. Serum concentrations of cobalamin, folate, trysin-like immunoreactivity (TLI),  
and pancreatic lipase immunoreactivity (PLI) for the cats with chronic GI disease. 
 
n.d. low, not determinable low 
NA, not available 
Cat ID 
Serum 
cobalamin 
(ng/L) 
Serum folate 
(µg/L) 
Serum TLI 
(µg/L) 
Serum PLI 
(µg/L) 
  
 ref: >290 
ng/L 
 ref: 9.7-21.6 
µg/L 
ref: 12-82  
µg/L 
ref: 2-6.8 
µg/L 
GROUP A 
    
A-1 1201 25 72.7 n.d. low 
A-2 1201 11.7 47.9 2.6 
A-3 671 23 119.5 1.2 
A-4 1100 12.3 54.9 8.1 
A-5 153 16 145.9 7.5 
A-6 691 19.4 76.2 1.8 
A-7 994 14.4 56.8 7 
A-8 NA NA NA NA 
GROUP B     
B-1 99 19.5 134.1 9.5 
B-2 252 17.8 68.4 5.5 
B-3 99 15.2 154.5 54.8 
B-4 99 10.9 107.1 12.1 
B-5 153 17.8 93.1 9.5 
B-6 NA NA NA NA 
B-7 139 7.1 206.7 35 
B-8 99 16.6 41.5 4.8 
B-9 287 16.5 102.3 4.1 
B-10 99 13.6 29.1 6.1 
B-11 1201 14 58.7 3.7 
B-12 668 13.6 112.5 5.9 
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Figure 4. Fecal α1-PI concentrations in 20 apparently healthy cats and 20 cats with 
chronic GI disease (Group A: mild to moderate IBD; Group B: severe IBD or 
gastrointestinal neoplasia). Both cats of Group A (median: 3.9 µg/g, range: 1.3 to 9.2 
µg/g) and those of Group B (median: 20.6 µg/g, range: 4.3 to 233.6 µg/g) had 
statistically significant different fecal α1-PI concentrations compared to healthy cats 
(median: 0.51, range: 0.04-1.72), (1-way ANOVA; P<0.001, P<0.001, respectively). 
Fecal α1-PI concentrations were also statistically significant between Groups A and B (1-
way ANOVA; P<0.01). 
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DISCUSSION 
Our study represents the first evaluation of fecal α1-PI concentrations in cats with 
chronic GI disease. We found that, except one cat with low disease severity, cats with 
gastrointestinal disease had increased fecal α1-PI concentrations when compared to a 
group of apparently healthy cats. These data suggest that increased fecal α1-PI 
concentrations may be common in cats with IBD and cats with GI neoplasia, such as 
lymphoma or carcinoma. Furthermore, fecal α1-PI concentrations were significantly 
higher in cats with severe IBD or confirmed GI neoplasia (Group B) when compared to 
cats with mild to moderate IBD (Group A; Figure 4). This is not an unexpected finding, 
as cases with more severe histopathological lesions (as in cats of Group B in our study) 
likely have more mucosal disruption and therefore greater transmucosal protein loss. 
Fecal α1-PI, which is referred to as α1-antitrypsin in human medicine, was shown to be 
increased in human patients with inflammatory bowel disease, such as Crohn’s disease, 
compared to healthy controls (Thomas et al., 1981). Similarly, a previous study in dogs 
showed that fecal α1-PI concentrations were significantly higher in dogs with chronic GI 
disease associated with histological abnormalities compared to dogs with clinical signs 
of chronic GI disease but normal histology or healthy control dogs (Murphy et al., 2003).  
We consider mucosal damage with subsequent loss of plasma as the most likely 
source of increased α1-PI concentrations in feces. In humans and various other 
mammalian species, α1-PI also has been reported to be produced by intestinal epithelial 
cells. However, this has not been found to be the case in carnivores (Satoh et al., 1990). 
Intestinal blood loss (hematochezia or melena) without evidence of GI mucosal disease 
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also may cause increased fecal α1-PI concentrations; however one study has shown that 
even moderate rectal bleeding does not affect fecal α1-PI determination in human 
patients (Grill et al., 1984). Although overt blood was not noted on the feces of any of 
the diseased cats in our study, we cannot completely rule out the possibility of some 
minor bleeding contributing to the increased concentration of α1-PI in the feces in some 
cats.  
In the majority of the diseased cats in this study, increased fecal α1-PI 
concentrations occurred in association with hypoproteinemia due to hypoalbuminemia. 
These results suggest that increased fecal α1-PI concentrations in association with 
hypoalbuminemia concentrations may be a common finding in cats with IBD and GI 
neoplasia. In dogs with chronic enteropathies, hypoalbuminemia has further been shown 
to be a negative prognostic indicator (Allenspach et al., 2007). Hypoalbuminemia has 
been reported in association with GI inflammation in cats; however, with less frequency 
(Dennis et al., 1992; Hart et al., 1994; Jergens et al., 1992). Previous studies also have 
stated that hypoproteinemia is much less common in cats than dogs with GI disease, and 
that cats appear to develop PLE less frequently than dogs (Lecoindre and Chevallier, 
1997; Baez et al., 1999; Peterson and Willard, 2003). In our study, the prevalence of 
hypoproteinemia was higher in cats of Group B (100%) compared to cats of Group A 
(57%), suggesting that protein loss via the damaged mucosa occurs more frequently in 
cases with more severe histological lesions. Panhypoproteinemia is an important 
indicator of protein-losing enteropathy as opposed to renal or hepatic disease, in which 
hypoproteinemia is usually caused by hypoalbuminemia alone. In our study, 
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panhypoproteinemia was present in 38% of all diseased cats, with Group B cats being 
panhypoproteinemic more frequently (55%) than cats in Group A (14%). 
One cat in Group A (A-5) had fecal α1-PI concentrations within the reference 
interval while the serum albumin concentration was subnormal. This cat was diagnosed 
with moderate IBD, and records also revealed concurrent severe chronic 
cholangiohepatitis and portal hepatitis. The cause of the subnormal serum albumin 
concentration in this cat remains unclear. It is possible that additional fecal samples from 
this cat may have shown increased α1-PI concentrations. We have previously shown that 
healthy cats had significant variations of fecal α1-PI concentrations (coefficient of 
variation: 47%) between samples of three consecutive days (Burke et al., 2012). It 
appears likely that fecal α1-PI concentrations may also vary in cats with GI disease, and 
we therefore prefer a minimum of three samples from consecutive days. Further, 
insufficient protein synthesis due to hepatitis may have also contributed to the low 
albumin concentration in this cat.  No other cats were diagnosed with overt hepatic or 
renal disease. Other potential causes for hypoalbuminemia, such as hemorrhage or 
dermal burns were not reported in any of the cats.  Albumin is also a negative acute 
phase protein, meaning that plasma concentrations can decrease in cases of acute 
inflammation. In our study, clinical disease of the cats had been observed for several 
weeks or months, thus it is unlikely that the GI disease of these cats was acute. Given 
that chronic signs of GI disease and histopathologic lesions were present, and other 
causes of hypoalbuminemia had been excluded out before enrolling the cats, intestinal 
50 
 
   
 
protein loss was the most likely cause for the hypoalbuminemia observed in these cats 
with increased fecal α1-PI concentrations.  
Hypocobalaminemia has most commonly been reported in cats with severe GI 
disease or exocrine pancreatic insufficiency (Simpson et al., 2001). Chronic mucosal 
disease of the ileum may cause destruction or reduced expression of cobalamin-intrinsic 
factor receptors, which can lead to cobalamin malabsorption and eventually to 
cobalamin deficiency. Thus, after excluding exocrine pancreatic insufficiency (acinar 
cells are the source of intrinsic factor in the cat), subnormal serum cobalamin 
concentrations are highly suggestive of distal small intestinal disease. In our study, 
hypocobalaminemia was observed in 56% of all cats with chronic GI disease, and was 
especially frequent in the cats of Group B (81%). Hypocobalaminemia was present in all 
cats in Group B that were diagnosed with severe GI inflammation or GI lymphoma, 
diseases commonly involving the ileum. Only two cats in this group had 
normocobalaminemia, both of which were diagnosed with adenocarcinoma of the colon. 
None of the cats in our study had decreased serum TLI concentrations, therefore EPI as a 
cause of hypocobalaminemia was ruled out. Hypocobalaminemia was infrequent in the 
cats with mild or moderate IBD (Group A, 1/7). It is possible that the lower degree of 
mucosal disease in these cats did not diminish cobalamin absorption significantly and / 
or that cobalamin malabsorption had not been present sufficiently long to deplete body 
stores. 
Folate represents a marker for proximal intestinal disease, as this is the location 
of specific folate carriers. Similar to cobalamin receptors in the distal intestine, folate 
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carriers in the proximal intestine may be damaged with mucosal disease, thus leading to 
folate malabsorption, subsequent depletion of folate stores, and, eventually, to folate 
deficiency. Folate was decreased in only one cat from Group B. This low frequency of 
decreased folate concentrations may be due to absence or insignificant mucosal damage 
of the proximal intestine in these cats. Alternatively, malabsorption may have been 
present, but folate stores were not depleted. Also, serum folate concentration may have 
been falsely normal or increased in patients with cobalamin deficiency, as cobalamin 
acts as a cofactor for an enzymatic pathway, which uses folate. Increased serum folate 
concentrations, as present in one cat from Group A, have no known clinical significance 
in cats. 
Serum fPLI is currently considered to be the most sensitive test for the diagnosis 
of pancreatitis in cats, being superior to both fTLI and abdominal ultrasound (Forman et 
al., 2004). Two cats in Group A presented with slightly increased serum fPLI 
concentrations, both of which were not in the range suggestive for pancreatitis (≥ 12 
µg/L). In contrast, five of the cats diagnosed with severe IBD or neoplasia (Group B) 
had increased serum fPLI concentrations; three of these values were suggestive of 
pancreatitis. The presence of pancreatitis in some of the cats in our study is not 
surprising, as coexistence of IBD and pancreatitis has been reported previously (Weiss et 
al., 1996; Meneses et al., 2003). The three cats with apparent pancreatitis also had 
concurrent hypoalbuminemia and hypocobalaminemia. A recent study has shown that 
hypocobalaminemia and hypoalbuminemia were more frequent in cats with IBD that had 
a concurrently increased serum fPLI concentration (Bailey et al., 2010). 
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All three cats with serum fPLI concentrations suggestive of pancreatitis also had 
increased serum fTLI concentrations. Three of the four cats with slightly increased 
serum fPLI concentrations (6.9 to <12 µg/L) also had increased serum fTLI 
concentrations. However serum fTLI concentrations were also increased in three cats in 
which the serum fPLI concentration was within the reference interval. Increases of 
serum fTLI concentrations in cats with IBD have been reported previously; however the 
reason for this is not known (Simpson et al., 2001). 
There are some limitations associated with our study. First, we were only able to 
obtain a single fecal sample from each cat for the fecal α1-PI assay. As mentioned above, 
we have previously reported significant variations of fecal α1-PI concentrations between 
samples of three consecutive days in healthy cats (Burke et al., 2012). We therefore 
recommend analysis of three fecal samples from consecutive days and calculation of the 
mean fecal α1-PI concentration. However, despite only having a single fecal sample 
available for the current study, we were able to demonstrate that fecal α1-PI 
concentration was statistically significant different between the two groups. However, 
only having a single sample available may have led to the fecal α1-PI within the normal 
range identified in one of the hypoalbuminemic cats in Group A. 
The number of cats for each group was low. For example, we only were able to 
enroll two cats with severe IBD. Therefore, we were not able to create a separate group 
for this category. We decided to place these two cats into Group B, because severe IBD 
is often difficult to differentiate from neoplastic disease, and because progression of 
lymphocytic inflammation to lymphoma has been proposed (Wilcock, 1992; Hart et al., 
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1994; Krecic, 2001). Finally, histopathological evaluations were performed by several 
pathologists. A previous study has shown significant inter-observer variation regarding 
histopathological interpretations of feline and canine intestinal tissues (Willard et al., 
2002). In that study, pathologists were from different institutions. In contrast, all 
pathologists in our study were from the same institution (AMC, NY) and cooperation 
between pathologists occurred, which likely created a more standardized grading scheme 
within this institution when compared to the study previously reported. 
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CHAPTER IV 
 
DISCUSSION 
 
In the first part of our study, we successfully developed and analytically 
validated an immunoassay for the measurement of α1-PI in feces and serum of cats. In 
comparison to the previously developed radioimmunoassay for the measurement of α1-PI 
in serum (Fetz et al., 2004), this new ELISA can be utilized to quantify α1-PI in both 
serum and fecal samples from cats.  Other advantages of the ELISA compared to the 
RIA include the faster turn-around time (about 6 hours) and the avoidance of radioactive 
material. Results of the validation of the ELISA demonstrated sufficient linearity, 
accuracy, precision, and reproducibility for both serum and fecal samples of cats.  
Although, α1-PI has been identified and purified in many different species, assays 
that can be used to quantify this protein in biological fluids have, thus far, been limited 
to humans and dogs. The availability of assays usually depends on the clinical need for 
such an assay. Assays for the measurement of α1-PI in serum from humans were 
developed for the identification of α1-PI deficiency, which is a common condition in 
people, but has not yet been reported in other species. Alpha1-PI is also an acute phase 
protein in a few species, including humans, rats, and rabbits. However, other serum 
markers, e.g., C-reactive protein, are routinely used to monitor the acute phase 
responses. Its relative abundance in plasma, coupled with its unique property of being 
resistant to proteolysis, makes α1-PI a suitable marker for intestinal protein loss. Protein-
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losing enteropathies have been associated with many different disease conditions in 
humans and dogs, while fewer reports exist in cats. The ELISA for feline α1-PI 
developed in this study is technically quite similar to the assay previously developed for 
use in dogs.  
In the second part of our study we evaluated fecal α1-PI concentrations as a 
marker of gastrointestinal protein loss in cats with chronic gastroenteropathies. Protein-
losing enteropathies have been associated with a variety of disease conditions in dogs, 
including idiopathic inflammatory bowel disease, intestinal lymphoma, and 
lymphangiectasia. Generally, a diagnosis of PLE can be assumed when 
hypoalbuminemia is present and other conditions that can cause hypoalbuminemia (e.g., 
renal loss, hepatic failure, blood loss, or cutaneous lesions) have been excluded. 
Although hypoproteinemia and hypoalbuminemia have been reported in cats with 
gastroenteropathies, the term PLE is rarely used in cats. One reason may be that, thus 
far, intestinal protein loss could not be readily diagnosed in cats due to the lack of a 
confirmatory test. Another reason may be that hypoalbuminemia appears to be less 
frequent and less severe in cats compared to dogs with gastrointestinal disease, and 
therefore may not be regarded as a significant complication in this species. 
Hypoalbuminemia is usually noted at a time when the disease is long-standing and 
severe. At that time, protein synthesis by the liver can no longer fully compensate for the 
continuous intestinal loss of protein. The quantification of α1-PI in fecal matter allows 
the detection and quantification of intestinal protein loss. This method therefore has the 
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potential to identify PLE much earlier in the disease process and likely before 
hypoalbuminemia or severe clinical signs are present. 
We showed that increased fecal α1-PI concentrations were present in the majority 
of the diseased cats compared to healthy controls. Our study, therefore, provides direct 
evidence that intestinal protein loss also does occur in cats with chronic gastrointestinal 
disease. The study design should be regarded as a pilot study as we could only enroll a 
relatively low number of healthy and diseased cats. In addition, only a single fecal 
sample was available from the diseased cats, while we generally recommend the 
collection of three fecal samples from consecutive days.  Interestingly, we also found 
that fecal α1-PI concentrations were higher in cats with greater severity of 
histopathological lesions. This finding was not unexpected as more transmucosal protein 
exudation can be expected with more severe histopathological lesions. Similar findings 
have also been reported in a study of dogs with chronic gastrointestinal disease (Murphy 
et al., 2003).  
Comparison of fecal excretion of α1-PI with that of radioactively labeled 
leukocytes correlated well in one study in humans (Fischbach et al., 1987), but not in 
another (Crama-Bohbouth, 1989). This suggests that gastrointestinal protein loss does 
not only depend on mucosal inflammation, and that gastrointestinal protein loss is not 
always a marker of mucosal inflammation. Fecal biomarkers for intestinal inflammation, 
such as calprotectin (S100A8/A9) and S100A12 recently have become available in dogs 
(Heilmann et al., 2008, Heilmann et al., 2011). Should these assays become available for 
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use in cats, it would be interesting to compare these fecal inflammatory markers with 
fecal α1-PI concentration in cats with chronic GI disease. 
  Hypoproteinemia and hypoalbuminemia have previously been associated with 
IBD and intestinal lymphoma in cats. For example, Jergens et al. (1992) found 
hypoalbuminemia in 24% of cats with IBD. Another study by Baez at al. (1999) reported 
hypoproteinemia and hypoalbuminemia in 24% and 15% of cats with IBD, respectively. 
Mahony et al. (1995) found mild hypoalbuminemia in 23% of cats with intestinal 
lymphoma, while low-grade intestinal lymphoma was not associated with 
hypoalbuminemia in a study by Lingard et al. (2009). Compared to these previous 
studies, hypoalbuminemia and hypoproteinemia were observed much more frequently in 
the cats with IBD (71% and 57%, respectively) or cats with neoplasia (100% and 100%, 
respectively) in our study. It is possible that the cats with IBD in our study had disease 
of a more pronounced severity compared to cats of other studies. Further, overall 
neoplastic disease in the cats of our study was possibly in more advanced stages than in 
previous studies, which may explain the higher prevalence of hypoalbuminemia and 
hypoproteinemia. 
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CHAPTER V 
 
CONCLUSIONS 
 
 
We conclude that the ELISA for the measurement of feline α1-PI concentrations 
in serum and fecal samples from cats described here is sufficiently linear, accurate, 
precise, and reproducible. 
Further, this is the first study investigating fecal α1-PI concentrations as a marker 
of GI protein loss in cats with IBD or GI neoplasia. We showed that increased fecal α1-
PI concentrations were present in the vast majority of the diseased cats compared to 
healthy controls and that fecal α1-PI concentrations were higher in cats with greater 
severity of histopathological lesions. The frequent presence of hypoalbuminemia in these 
cats further suggests a protein-losing syndrome as it has been described in humans and 
dogs with chronic gastroenteropathies before. Further studies with larger groups of 
healthy and diseased cats are warranted for the clinical evaluation of this assay.
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